Depression in people with alopecia areata
Part of Mental health, Skin clinical trials.
This study checks how common depression is in people with alopecia areata. By joining, you help doctors understand the emotional impact of hair loss and may get extra support.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have alopecia areata, a condition that causes patchy hair loss.
- You must be 18 years old or older.
- You must be willing to attend the dermatology clinic at Sohag University Hospital and sign a consent form.
- You must not have another cause of hair loss (like a different scalp condition).
- You must not have been diagnosed with a mental health disorder before your alopecia areata diagnosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at depression among medical students aged 18 to 25 at Sohag University. It aims to understand how common depression is in this group and may help improve support for students.
This study tracks the safety and effectiveness of alopecia areata treatments in teenagers aged 12-17. It helps doctors understand which treatments work best and are safest for young people with severe hair loss.
This registry collects information from adults with alopecia areata who are starting or taking certain approved medications. It helps researchers understand how well these treatments work and how safe they are in real-world care.
This study tests an oral medication (SYHX1901) for severe alopecia areata, a condition where the immune system attacks hair follicles, causing significant hair loss. If you qualify, you may receive the study drug to see if it helps regrow hair and improve your condition.
This study tests an investigational drug to see if it can help people with severe alopecia areata, a condition that causes hair loss. It may help regrow hair.
This trial tests a new drug called FB102 for people with severe to very severe alopecia areata, a condition that causes at least half of scalp hair to be lost. It aims to see if the drug is safe and can help hair grow back.
Hear when a new Depression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.